Introduction Type 2 diabetes mellitus (T2DM) requires long-term pharmacologic therapy, with treatment choice influenced by efficacy, tolerability, and safety (1). Metformin is the first-line agent, but alternative or combination therapies are often necessary (1). Dipeptidyl peptidase-4 (DPP-4) inhibitors have become attractive options owing to weig

Introduction: Dipeptidyl peptidase-4 inhibitors (DPP4is) are widely used oral antidiabetic agents in type 2 diabetes mellitus (T2DM) (1). They act by enhancing endogenous incretin activity, which promotes glucose-dependent insulin secretion and suppresses glucagon release (1). DPP4is demonstrate modest HbA1c (glycated haemoglobin) reduction of abou

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  FDA Approves First RNA-Targeted Therapy for Hereditary Angioedema The FDA has approved donidalorsen for preventing attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 and above. The RNA-targeted therapy reduces plasma

Introduction Atorvastatin, a potent HMG-CoA reductase inhibitor, has been widely used for lowering low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidaemia and established coronary heart disease (CHD) (1). While moderate-intensity statin therapy is well established in secondary prevention, the incremental benefit of intensive st

Introduction Hyperlipidaemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD) (1). It is commonly characterized by elevated low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and reduced high-density lipoprotein cholesterol (HDL-C) (1). Statins are the first-line pharmacological therapy, with atorvast

In this insightful Key Opinion Leader (KOL) interview, we sit down with Dr. Chetan Purad, a renowned Diabetologist from Hyderabad, Telangana, India, to explore the intersection of women’s health and metabolic medicine. From PCOS (Polycystic Ovary Syndrome) to insulin resistance and broader metabolic health challenges, Dr. Purad sheds light on the r

Introduction Type 2 diabetes mellitus (T2DM) is a progressive chronic condition that often requires combination therapy to achieve optimal glycemic control while minimizing the risk of complications (1). Beyond glucose lowering, modern treatment goals emphasize organ protection, especially cardiovascular and renal outcomes (1). Fixed-dose combinati

Introduction Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, progressive β-cell dysfunction, and persistent hyperglycemia (1). Beyond glycemic dysregulation, T2DM contributes significantly to microvascular and macrovascular complications, with diabetic nephropathy (DN) being one of the most serio

Introduction Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder associated with microvascular and macrovascular complications, including cardiovascular disease and chronic kidney disease (1). Sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as dapagliflozin, have emerged as effective glucose-lowering therapies with addition